Xinhua Silk Road - Belt and Road Portal, China's silk road economic belt and 21st Century Maritime Silk Road Website Xinhua Silk Road - Belt and Road Portal, China's silk road economic belt and 21st Century Maritime Silk Road Website
Subscribe CustomBlackClose

Belt & Road Weekly Subscription Form

download_pop

Research ReportCustomBlackClose

The full edition of the report is available at Xinhua Silk Road Database. You can click the “Table of Content” to have a general understanding of it.

Click on the button below to create your account and get immediate access to thousands of articles.

Start a Free Trial

Xinhua Silk Road
Company

China's BeiGene extends gains on launch of new firm with U.S. biopharma

June 19, 2019


Abstract : BeiGene, a Chinese biotechnology company, saw its shares rise by 2.2 percent on Tuesday after it announced it co-founded a new firm with U.S. biopharmaceutical firm SpringWorks, in efforts to combat cancer.

NEW YORK, June 18 (Xinhua) -- BeiGene, a Chinese biotechnology company, saw its shares rise by 2.2 percent on Tuesday after it announced it co-founded a new firm with U.S. biopharmaceutical firm SpringWorks, in efforts to combat cancer.

BeiGene's stock price in Nasdaq settled at 116.53 U.S. dollars per share around market close. The Beijing-based company was valued at nearly 6.97 billion U.S. dollars in market capitalization by Tuesday.

The new entity, named MapKure, is part of BeiGene's efforts to develop "innovative medicines for cancer patients with few or no treatment options," according to John Oyler, co-founder and chairman of BeiGene.

SpringWorks Therapeutics, a clinical-stage biopharma founded in 2017, jointly owns MapKure with an equity investment.

MapKure plans to develop a new drug called BGB-3245 that could help inhibit certain forms of mutations that have been identified in some solid tumors as drivers of their cancerous growth, such as non-small cell lung cancer, colorectal cancer, thyroid cancer, and brain tumors, according to BeiGene's statement on Tuesday.

The selective small molecule inhibitor BGB-3245 was discovered by BeiGene's scientists and is currently in preclinical development.

Scan the QR code and push it to your mobile phone

Keyword: China medicine

Reading:

Investment group expands its China portfolio

Jing'an women's marathon to raise breast cancer awareness

​CMC-invested PV power station in Hungary starts construction

Chongzuo City

Laibin City

Write to Us belt & road login close

Do you want to be a contributor to Xinhua Silk Road and tell us your Belt & Road story? Send your articles to [email protected] and share your stories with more people.

Click on the button below to create your account and get im http://img.silkroad.news.cn/templates/silkroad/en2017te access to thousands of articles.

Start a Free Trial

Ask Us A Question belt & road login close

If you have any questions, please enter them in the box below.

Identifying code Reload

Write to Us belt & road login close

Do you want to be a contributor to Xinhua Silk Road and tell us your Belt & Road story? Send your articles to silkroadweekly@xinhua.org and share your stories with more people.

Click on the button below to create your account and get im http://img.silkroad.news.cn/templates/silkroad/en2017te access to thousands of articles.

Start a Free Trial